Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson’s Disease: A Case Report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson’s Disease: A Case Report

Published:2018-06-08 Issue: Volume:9 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Trifirò Gianluca,Marcianò Ilaria,Cutroneo Paola M.,Spina Edoardo,Mirabelli Eliana,Trombetta Costantino J.,Morgante Francesca

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference44 articles.

1. The relationship between cerebral vascular disease and parkinsonism: the VADO study.;Antonini;Parkinsonism Relat. Disord.,2012

2. Venturing into the no-man’s land of the retina in Parkinson’s disease.;Bodis-Wollner;Mov. Disord.,2014

3. Mining retrospective data for virtual prospective drug repurposing: L-DOPA and age-related macular degeneration.;Brilliant;Am. J. Med.,2016

4. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.;Brown;N. Engl. J. Med.,2006

5. Increased risk of Parkinson disease following a diagnosis of neovascular age-related macular degeneration: a retrospective cohort study.;Chung;Am. J. Ophthalmol.,2014

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update;BioDrugs;2021-10-16

2. Assessing intravitreal anti-VEGF drug safety using real-world data: methodological challenges in observational research;Expert Opinion on Drug Safety;2021-07-27

3. Vascular endothelial growth factor‐loaded poly‐lactic‐co‐glycolic acid nanoparticles with controlled release protect the dopaminergic neurons in Parkinson's rats;Chemical Biology & Drug Design;2020-03-29

4. Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports;Frontiers in Pharmacology;2020-03-12

5. Ranibizumab;Reactions Weekly;2018-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3